A Phase 1/2a First-in-human Study to Evaluate the Safety, Tolerability and Efficacy of IMA401, a bispecific T cell engaging receptor molecule (TCER®) in patients with recurrent and/or refractory solid tumors.
Laufzeit: 01.01.2021 - 31.12.2027
imported
Kurzfassung
A Phase 1/2a First-in-human Study to Evaluate the Safety, Tolerability and Efficacy of IMA401, a bispecific T cell engaging receptor molecule (TCER) in patients with recurrent and/or refractory solid tumors
Beteiligte Einrichtungen
